Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer...

Can AI predict and prevent brain disorders like Alzheimer's? Yes! Discover how AI is transforming neurological care for a healthier future.

Understanding the impact of extreme weather on neurological conditions is becoming increasingly crucial as climate change intensifies. The study,...

European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...

Highlights: Artificial Intelligence (AI) can detect neurological diseases early, sometimes before symptoms appe

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt...

A Changing Landscape The emergence of mobile technology, social media, and high-speed internet has democratized live reporting, allowing...

While AEM is well-placed on a strong pipeline of growth projects, solid financial health and a healthy growth trajectory, its high costs warrant...